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background:  Prasugrel, a potent thienopyridine, achieves better platelet inhibition than clopidogrel. However, the onset of effect is 
significantly delayed in patients with acute ST-elevation myocardial infarction (STEMI), whereby a strong relationship with hemodynamic 
stability and morphine application is observed. Since a rapid onset of effect is observed in NSTEMI patients also after percutaneous 
coronary intervention (PCI) without increasing cardiovascular event rate, we assessed the efficacy of prasugrel loading immediately after 
PCI for STEMI instead of preloading the unstable patient before revascularization.
methods:  We investigated 29 consecutive patients with acute STEMI (mean age 56±2 years) admitted to our department who underwent 
primary PCI. Prasugrel efficacy was assessed by the platelet-reactivity-index (PRI; VASP assay) before and 1, 2, 4, 6, 12, and 24 hours 
following an oral loading dose of 60mg immediately after primary PCI. High on-treatment platelet reactivity (HTPR) was defined as a 
PRI>50%.
Results:  During the observed period, prasugrel highly significantly and rapidly reduced platelet reactivity determined by PRI in acute 
STEMI patients (p=0.0002). In detail, mean PRI (±SEM) was 72±2% before (control) and 47±6% at 1h (p<0.001 vs. control), 25±5% at 2h 
(p<0.001 vs. control), 22±5% at 4h (p<0.001 vs. control), 20±5% at 6h (p<0.001 vs. control), 12±3% at 12h (p<0.001 vs. control), and 9±2% 
at 24h (p<0.001 vs. control) after loading. The HTPR rate was 45% at 1h, 21% at 2h, 18% at 4h, 11% at 6h, 4% at 12h, and 0% at 24h.
conclusion:  In contrast to previous reports describing a significant delay in onset of prasugrel-mediated P2Y12 inhibition in acute STEMI, 
we observed a rapid onset with low HTPR rates comparable to those observed in stable non-STEMI or elective PCI patients. Prasugrel 
given directly after primary PCI might therefore be a useful therapeutic strategy in patients with STEMI to provide strong and effective 
P2Y12 inhibition.
